Katherine M Aird

List of Publications by Year
in descending order

37 papers	2,516 citations	279798 23 h-index	345221 36 g-index
45 all docs	45 docs citations	45 times ranked	4965 citing authors

#	Article	IF	Citations
1	53BP1: guarding the genome with a novel liquid weapon. Communications Biology, 2022, 5, 435.	4.4	0
2	The senescence-associated secretory phenotype in ovarian cancer dissemination. American Journal of Physiology - Cell Physiology, 2022, 323, C125-C132.	4.6	2
3	Suppression of p16 alleviates the senescence-associated secretory phenotype. Aging, 2021, 13, 3290-3312.	3.1	34
4	Loss of p16: A Bouncer of the Immunological Surveillance?. Life, 2021, 11, 309.	2.4	10
5	DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A. Journal of Cell Biology, 2021, 220, .	5.2	35
6	Overexpression of oncogenic H-Ras in hTERT-immortalized and SV40-transformed human cells targets replicative and specialized DNA polymerases for depletion. PLoS ONE, 2021, 16, e0251188.	2.5	2
7	Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells. Oncogene, 2020, 39, 1619-1633.	5.9	37
8	ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. Heliyon, 2020, 6, e05097.	3.2	4
9	Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers. Cellular and Molecular Bioengineering, 2020, 13, 447-461.	2.1	11
10	Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence. Nature Communications, 2020, 11, 908.	12.8	36
11	NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer. JCI Insight, 2020, 5, .	5.0	43
12	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. Cell Reports, 2019, 28, 1971-1980.e8.	6.4	42
13	p16: cycling off the beaten path. Molecular and Cellular Oncology, 2019, 6, e1677140.	0.7	17
14	Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer. Molecular Cancer Research, 2019, 17, 1710-1720.	3.4	36
15	NAD+ metabolism governs the proinflammatory senescence-associated secretome. Nature Cell Biology, 2019, 21, 397-407.	10.3	232
16	GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment. Redox Biology, 2019, 25, 101051.	9.0	41
17	Simultaneous isotope dilution quantification and metabolic tracing of deoxyribonucleotides by liquid chromatography high resolution mass spectrometry. Analytical Biochemistry, 2019, 568, 65-72.	2.4	14
18	Jumonji C Demethylases in Cellular Senescence. Genes, 2019, 10, 33.	2.4	16

#	Article	IF	Citations
19	CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Scientific Reports, 2018, 8, 14725.	3.3	35
20	Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. Frontiers in Endocrinology, 2018, 9, 177.	3.5	58
21	ARID1A-mutated ovarian cancers depend on HDAC6Âactivity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173
22	Ovarian cancer: how can resistance to chemotherapy be tackled?. Future Oncology, 2017, 13, 2737-2739.	2.4	9
23	Ataxia-Telangiectasia Mutated Modulation of Carbon Metabolism in Cancer. Frontiers in Oncology, 2017, 7, 291.	2.8	36
24	HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. Journal of Cell Biology, 2016, 215, 325-334.	5.2	132
25	Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Molecular Cancer Research, 2016, 14, 767-775.	3.4	27
26	Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and <i>ARID1A</i> mutations. Molecular and Cellular Oncology, 2016, 3, e1032476.	0.7	21
27	EglN2 associates with the <scp>NRF</scp> 1â€‹<scp>PGC</scp> 1Î± complex and controls mitochondrial function in breastÂcancer. EMBO Journal, 2015, 34, 2953-2970.	7.8	58
28	SPOP E3ÂUbiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Reports, 2015, 13, 1183-1193.	6.4	55
29	ATM Couples Replication Stress and Metabolic Reprogramming during Cellular Senescence. Cell Reports, 2015, 11, 893-901.	6.4	94
30	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 2015, 21, 231-238.	30.7	530
31	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8638-8643.	7.1	174
32	Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Letters, 2015, 356, 204-210.	7.2	109
33	ATM in senescence. Oncotarget, 2015, 6, 14729-14730.	1.8	13
34	Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle, 2014, 13, 199-207.	2.6	36
35	Metabolic alterations accompanying oncogene-induced senescence. Molecular and Cellular Oncology, 2014, 1, e963481.	0.7	26
36	Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Reports, 2013, 3, 1252-1265.	6.4	228

#	Article	IF	Citations
37	Oncogenic Ras Regulates BRIP1 Expression to Induce Dissociation of BRCA1 from Chromatin, Inhibit DNA Repair, and Promote Senescence. Developmental Cell, 2011, 21, 1077-1091.	7.0	82